XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer.
Phase 2
Recruiting
- Conditions
- nresectable or recurrent colorectal cancer
- Registration Number
- JPRN-UMIN000005191
- Lead Sponsor
- Hematology and Oncology, Kyushu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Exclusion Criteria
Double cancer, severe allergic history, active infections, severe complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Response rate Time to treatment failure Overall survival Safety plofiles(Rate of Grade 3 neurotoxicity, adverse events)